CT perfusion core and ASPECT score prediction of outcomes in DEFUSE 3.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 3 4 2020
medline: 26 10 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

The role of Alberta Stroke Program Early CT Score (ASPECTS) for thrombectomy patient selection and prognostication in late time windows is unknown. We compared baseline ASPECTS and core infarction determined by CT perfusion (CTP) as predictors of clinical outcome in the Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE) 3 trial. We included all DEFUSE 3 patients with baseline non-contrast CT and CTP imaging. ASPECTS and core infarction were determined by the DEFUSE 3 core laboratory. Primary outcome was functional independence (modified Rankin Scale (mRS) ≤2). Secondary outcomes included ordinal mRS shift at 90 days and final core infarction volume. Of the 142 patients, 85 patients (60%) had ASPECTS 8-10 and 57 (40%) had ASPECTS 5-7. Thirty-one patients (36%) with ASPECTS 8-10 and 11 patients (19%) with ASPECTS 5-7 were functionally independent at 90 days ( Higher ASPECTS (8-10) correlated with functional independence at 90 days in the DEFUSE trial. ASPECTS and core infarction volume did not modify the thrombectomy treatment effect, which indicates that patients with a target mismatch profile on perfusion imaging should undergo thrombectomy regardless of ASPECTS or core infarction volume in late time windows.

Sections du résumé

BACKGROUND
The role of Alberta Stroke Program Early CT Score (ASPECTS) for thrombectomy patient selection and prognostication in late time windows is unknown.
AIMS
We compared baseline ASPECTS and core infarction determined by CT perfusion (CTP) as predictors of clinical outcome in the Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE) 3 trial.
METHODS
We included all DEFUSE 3 patients with baseline non-contrast CT and CTP imaging. ASPECTS and core infarction were determined by the DEFUSE 3 core laboratory. Primary outcome was functional independence (modified Rankin Scale (mRS) ≤2). Secondary outcomes included ordinal mRS shift at 90 days and final core infarction volume.
RESULTS
Of the 142 patients, 85 patients (60%) had ASPECTS 8-10 and 57 (40%) had ASPECTS 5-7. Thirty-one patients (36%) with ASPECTS 8-10 and 11 patients (19%) with ASPECTS 5-7 were functionally independent at 90 days (
CONCLUSIONS
Higher ASPECTS (8-10) correlated with functional independence at 90 days in the DEFUSE trial. ASPECTS and core infarction volume did not modify the thrombectomy treatment effect, which indicates that patients with a target mismatch profile on perfusion imaging should undergo thrombectomy regardless of ASPECTS or core infarction volume in late time windows.

Identifiants

pubmed: 32233746
doi: 10.1177/1747493020915141
doi:

Banques de données

ClinicalTrials.gov
['NCT02586415']

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

288-294

Subventions

Organisme : NINDS NIH HHS
ID : U10 NS086487
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS092076
Pays : United States

Commentaires et corrections

Type : ErratumIn

Auteurs

May Kim-Tenser (M)

Department of Neurology, 5116University of Southern California, Los Angeles, CA, USA.

Michael Mlynash (M)

Department of Neurology, Stanford University, Palo Alto, CA, USA.

Maarten G Lansberg (MG)

Department of Neurology, Stanford University, Palo Alto, CA, USA.

Matthew Tenser (M)

Department of Neurosurgery, 5116University of Southern California, Los Angeles, CA, USA.

Sebina Bulic (S)

Department of Neurology, 5116University of Southern California, Los Angeles, CA, USA.

Bharathi Jagadeesan (B)

Department of Radiology, 5635University of Minnesota, Minneapolis, MN, USA.

Soren Christensen (S)

Department of Neurology, Stanford University, Palo Alto, CA, USA.

Alexis Simpkins (A)

Department of Neurology, University of Florida, Gainesville, FL, USA.

Gregory W Albers (GW)

Department of Neurology, Stanford University, Palo Alto, CA, USA.

Michael P Marks (MP)

Department of Radiology, Stanford University, Palo Alto, CA, USA.

Jeremy J Heit (JJ)

Department of Radiology and Neurosurgery, NeuroInterventional Radiology Section, Stanford University Medical Center, Stanford, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH